Jump to main content
Jump to site search

Issue 7, 2012
Previous Article Next Article

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Author affiliations

Abstract

Recently, the importance of targeted covalent inhibitors in addressing potency, selectivity and drug resistance has become of great interest, especially in the area of non-small cell lung cancer (NSCLC). Although several covalent EGFR TKIs that are advancing in NSCLC clinical development are active against mutations which are refractory to the reversible TKI drugs Tarceva and Iressa, limited chemical diversity has been explored; all of the irreversible and reversible clinical compounds share the same quinazoline scaffold. We describe the design of a novel pyrimidine-based irreversible inhibitor of EGFR (CNX17) which is active against both the WT EGFR as well as the resistance mutation L858R/T790M in biochemical assays. The inhibitor is also a potent inhibitor of EGFR signaling, including the L858R/T790M resistance mutation in cells (H1975 cell line, EC50 441 nM). Importantly, it also potently inhibits proliferation in both HCC827 (EGFRΔ746–750 EC50 < 5 nM) and H1975 (EC50 134 nM). This novel chemical scaffold may be an important addition to the armamentarium in overcoming drug resistance to current EGFR therapies.

Graphical abstract: Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Back to tab navigation

Supplementary files

Publication details

The article was received on 24 Jan 2012, accepted on 19 Apr 2012 and first published on 18 Jun 2012


Article type: Concise Article
DOI: 10.1039/C2MD20017A
Med. Chem. Commun., 2012,3, 780-783

  •   Request permissions

    Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

    J. Singh, E. Evans, M. Hagel, M. Labinski, A. Dubrovskiy, M. Nacht, R. C. Petter, A. Prasad, M. Sheets, T. St Martin, R. Tjin Tham Sjin, W. Westlin and Z. Zhu, Med. Chem. Commun., 2012, 3, 780
    DOI: 10.1039/C2MD20017A

Search articles by author

Spotlight

Advertisements